Join the Eczema group to help and get support from people like you.
Eczema News (Page 2)
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema
FRIDAY, Oct. 4, 2024 – For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has long-term efficacy, according to a study presented at the annual meeting of the European Academy...
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
WEDNESDAY, Sept. 18, 2024 – The U.S. Food and Drug Administration has approved Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis....
Link Between n-3 LCPUFA, Eczema Varies by Maternal COX1 Genotype
WEDNESDAY, Sept. 4, 2024 – The association of prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) with the risk for childhood atopic dermatitis (AD) varies based on the maternal ...
Dietary Vitamin E May Be Protective Against Atopic Dermatitis
FRIDAY, Aug. 30, 2024 – Dietary intake of vitamin E may potentially lower the risk for atopic dermatitis, according to a study published online Aug. 9 in Skin Research & Technology. Siqing Wang, ...
Obese Kids May Face Higher Odds for Eczema, Psoriasis
WEDNESDAY, Aug. 21, 2024 – Obese kids are more likely to develop immune-based skin problems like eczema or psoriasis, a new study says. Analysis of more than 2.1 million Korean children between 2009...
Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
MONDAY, Aug. 12, 2024 – For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8 percent of patients, according to a...
Gen Z Perceives Atopic Dermatitis to Be More Severe
TUESDAY, July 30, 2024 – Generation Z (Gen Z) patients present with a higher subjective perception of atopic dermatitis severity than millennial generation patients, according to a study published...
Atopic Dermatitis Has Large Impact on Sexual Function Among Women
MONDAY, July 29, 2024 – Most women with atopic dermatitis have impairment in sexual function, and about half consider that atopic dermatitis may influence their reproductive desire, according to a...
Atopic Dermatitis Has Large Impact on Sexual Function Among Women
MONDAY, July 29, 2024 – Most women with atopic dermatitis have impairment in sexual function, and about half consider that atopic dermatitis may influence their reproductive desire, according to a...
Adverse Event Risk Up for >90 Days Versus >30 Days of Corticosteroids for Eczema
WEDNESDAY, July 24, 2024 – Use of oral corticosteroids for >90 days during one year is associated with a slightly increased risk of adverse events (AEs), according to a study published online July...
Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect
TUESDAY, June 18, 2024 – Lebrikizumab is associated with sustained effects for moderate-to-severe atopic dermatitis for up to week 52 following withdrawal of treatment, according to a study...
High-Salt Diets Might Raise Eczema Risk
WEDNESDAY, June 5, 2024 – Doctors already warn folks off salt due to its heart risks, but new research suggests sodium isn't helping your skin either. Researchers found that as daily salt intake...
1.5 Percent Ruxolitinib Cream Safe, Effective for Teens With Eczema
FRIDAY, May 31, 2024 – Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD), according to a study...
Parental E-Cigarette Use Linked to Increase in Pediatric Atopic Dermatitis
TUESDAY, May 28, 2024 – Parental electronic cigarette use is associated with increased odds of pediatric atopic dermatitis (AD), according to a research letter published online May 22 in JAMA...
Parents' Vaping Might Help Spur Eczema in Kids
THURSDAY, May 23, 2024 – A mom or dad who vapes at home might be setting their child up for eczema, new research suggests. In a study involving data from over 35,000 U.S. households, children with a...
Further information
Related condition support groups
Related drug support groups
prednisone, methotrexate, clobetasol, Dupixent, fluocinonide, dexamethasone, desonide, dupilumab, halobetasol